Pharmacogenetics in labeling
Executive Summary
FDA's Clinical Pharmacology Subcommittee topics will include translation of pharmacogenetic information into label updates during a Nov. 14-15 meeting. Discussion of FDA's "Critical Path" initiative will occur on both days of the meeting. On Nov. 14, the subcommittee will discuss "end-of-Phase IIa" meetings. On 1Nov. 15, meeting topics will include several Critical Path-related issues, including the use of biomarker information in labels to facilitate individualizing pharmacotherapy. The meeting will be held at CDER's advisory committee conference room at 5630 Fishers Lane in Rockville, Md., beginning at 8:30 a.m. both days...
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.